Nestle Health Science enters microbiome research venture

929c1134-8d44-4139-8110-035684bd4b33articleimage.jpg

13 Jul 2017 --- Nestlé Health Science and Enterome are establishing Microbiome Diagnostics Partners (MDP), in an attempt to lead the development and commercialization of innovative microbiome-based diagnostics with the potential to transform therapeutic approaches across health conditions such as inflammatory bowel diseases (IBD) and liver diseases. The partnership follows Nestlé Health Science’s initial investment announced in April 2016.

“Mastering the microbiome is an important facet of our strategy to advance the therapeutic role of nutrition. We also see new opportunities for personalized nutrition both for the healthy population and for patients. The two initial programs have great potential to become differentiated diagnostics,” says Greg Behar, CEO of Nestlé Health Science.

According to the companies, MDP will initially aim to boost Enterome’s diagnostic programs, which include IBD 110 for the assessment and management of mucosal healing and MET210 for NASH (non-alcoholic steatohepatitis). The current standard of care for these conditions include invasive procedures such as endoscopy and biopsies, rather than a non-invasive stool/serum combined Dx tests that will be developed by MDP. Future innovation efforts will leverage advanced microbial and serum-based metabolic technologies developed respectively at Enterome and Nestlé Health Science’s diagnostics arm Prometheus Laboratories.

The companies announced that Microbiome Diagnostics Partners is to be a 50:50 joint venture between Enterome and Nestlé Health Science. Prometheus (a Nestlé Health Science Company) will contribute its Diagnostics (Dx) development and commercialization expertise. Enterome will contribute its current microbiome diagnostic programs and intellectual property (IP) derived from its unique microbiome-based platform for the development of Dx in all therapeutic areas except immuno-oncology. 

Nestlé Health Science will reportedly invest €20 million in return for its 50 percent stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities.

Commenting on the move, Behar says, “Microbiome Diagnostics Partners is equipped to lead diagnostic discovery in the microbiome field, opening the door to innovative therapeutic approaches combining diagnostics (Dx), nutritional therapies (Nx) and therapeutics (Rx).” 

“The formation of Microbiome Diagnostics Partners is an important milestone for Enterome, as it brings together powerful and complementary technologies and capabilities to enable the creation of a new generation of diagnostic and companion diagnostic products. The MDP joint venture will leverage Enterome’s microbiome-based platforms in diagnostic areas, while Enterome will continue to focus on their application for the discovery of novel small molecule therapeutics,” comments Pierre Belichard, CEO of Enterome.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

SlimBiome muesli to hit UK shelves

20 Jun 2018 --- Fruit, nut and seed supplier John Morley are teaming up with OptiBiotix health to deliver a weight-management breakfast muesli utilizing the SlimBiome technology. OptiBiotix’s patented Slimbiome claims to support weight-loss management by modifying the activity of the microbiome. The exclusive license granted to John Morley marks the first foray of SlimBiome into the UK breakfast market.

Nutrition & Health News

Personalized nutrition: Mindful and aware consumers drive market opportunity

19 Jun 2018 --- Personalized nutrition has taken its place as a key industry topic, spurring the launch of a number of innovative start-ups using cutting-edge technologies to offer precise nutrition advice to consumers. This growing industry space will be the topic of discussion at the Personalized Nutrition Innovation Summit, which is taking place in San Francisco on June 26-27.

Nutrition & Health News

Vitafoods Europe visitor numbers up 6 percent, cross-over themes in nutraceuticals trend

13 Jun 2018 --- Vitafoods Europe (Geneva, May 2018) has strongly established itself as one of the major events on the nutrition calendar, with significant growth in the dedicated show space in the last couple of years. The show attracted over 20,000 visitors, with attendance numbers reflecting a six percent increase from the previous year as well as exhibitor numbers also growing 8 percent from 2017. Vitafoods also demonstrated the expansion of nutraceuticals into other market areas such as foods, pharma, cosmetics and personalization.

Nutrition & Health News

Gut-brain axis: Multi-strain probiotic holds potential for IBS symptom relief 

12 Jun 2018 --- A multi-strain probiotic supplement has resulted in strong symptom reductions in those suffering from Irritable Bowel Syndrome – diarrhea  (IBS-D), a study conducted at the University of Bangabandhu Sheikh Medical University in Bangladesh has found. The 14 strains of “gut-friendly” bacteria in the supplement – Bio-Kult – were also found to reduce anxiety, tapping into the growing space of gut-brain axis products.

Nutrition & Health News

Fatty diets may desensitize us to the taste of fat, study suggests

06 Jun 2018 --- People who consume a high-fat diet may, in turn, eat more fatty foods as they become desensitized to its taste, a study has found. The study, published in The American Journal of Clinical Nutrition, used twins to examine how individuals may vary when following either a high-fat or low-fat diet. The diets altered the fat taste sensitivity of the participants and highlighted the importance of the environment for weight maintenance.

More Articles
URL : http://www.nutritioninsight.com:80/news/nestle-health-science-enters-microbiome-research-venture.html